Gamma Heavy-chain Disease: Defining the Spectrum of Associated Lymphoproliferative Disorders Through Analysis of 13 Cases : The American Journal of Surgical Pathology

Secondary Logo

Journal Logo

Original Articles

Gamma Heavy-chain Disease

Defining the Spectrum of Associated Lymphoproliferative Disorders Through Analysis of 13 Cases

Bieliauskas, Shannon DO*; Tubbs, Raymond R. DO*; Bacon, Chris M. MB ChB, PhD, FRCPath†,‡; Eshoa, Camellia MD§; Foucar, Kathryn MD; Gibson, Sarah E. MD; Kroft, Steven H. MD#; Sohani, Aliyah R. MD**; Swerdlow, Steven H. MD; Cook, James R. MD, PhD*

Author Information
The American Journal of Surgical Pathology 36(4):p 534-543, April 2012. | DOI: 10.1097/PAS.0b013e318240590a


Gamma heavy-chain disease (gHCD) is defined as a lymphoplasmacytic neoplasm that produces an abnormally truncated immunoglobulin gamma heavy-chain protein that lacks associated light chains. There is scant information in the literature regarding the morphologic findings in this rare disorder, but cases have often been reported to resemble lymphoplasmacytic lymphoma (LPL). To clarify the spectrum of lymphoproliferative disorders that may be associated with gHCD, this study reports the clinical, morphologic, and phenotypic findings in 13 cases of gHCD involving lymph nodes (n=7), spleen (n=2), bone marrow (n=8), or other extranodal tissue biopsies (n=3). Clinically, patients showed a female predominance (85%) with frequent occurrence of autoimmune disease (69%). Histologically, 8 cases (61%) contained a morphologically similar neoplasm of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that was difficult to classify with certainty, whereas the remaining 5 cases (39%) showed the typical features of one of several other well-defined entities in the 2008 WHO classification. This report demonstrates that gHCD is associated with a variety of underlying lymphoproliferative disorders but most often shows features that overlap with cases previously reported as “vaguely nodular, polymorphous” LPL. These findings also provide practical guidance for the routine evaluation of small B-cell neoplasms with plasmacytic differentiation that could represent a heavy-chain disease and give suggestions for an improved approach to the WHO classification of gHCD.

© 2012 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid